CRISPR-Cas9 genome editing to disrupt the CD7 expression and engineer CAR-T cells lacking CD7 and TCR alpha chain (TRAC) expression have demonstrated significant antitumor activity against T-ALL cell lines and primary human samples, as well as tumor regression in preclinical models with the absence of GvHD (55). Here, CD7 is linked to neoplasm.